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This initial report presents a neonatal rat model with exposure to a transient intermittent hypoxia (IH),
which results in a persisting diabetes-like condition in the young rats. Twenty-ﬁve male pups were trea-
ted at postnatal day 1 with IH exposure by alternating the level of oxygen between 10.3% and 20.8% for
5 h. The treated animals were then maintained in normal ambient oxygen condition for 3 week and com-
pared to age-matched controls. The IH treated animals exhibited a signiﬁcantly higher fasting glucose
level than the control animals (237.00 ± 19.66 mg/dL vs. 167.25 ± 2.95 mg/dL; P = 0.003); and a signiﬁ-
cantly lower insulin level than the control (807.0 ± 72.5 pg/mL vs. 1839.8 ± 377.6 pg/mL; P = 0.023). There
was no difference in the mass or the number of insulin producing beta cells as well as no indicative of
inﬂammatory changes; however, glucose tolerance tests showed a signiﬁcantly disturbed glucose
homeostasis. In addition, the amount of C-peptide secreted from the islets harvested from the IH animals
were decreased signiﬁcantly (from 914 pM in control to 809 pM in IH; P = 0.0006) as well. These obser-
vations demonstrate that the neonatal exposure to the IH regimen initiates the development of deregu-
lation in glucose homeostasis without inﬁltration of inﬂammatory cells.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Increasing evidence suggests that free radical mediated oxida-
tive stress could induce diabetes mellitus via an epigenetic etio-
logic pathway [1,2]. An excessive accumulation of reactive
oxygen species can elevate antioxidant enzymes, and then impair
beta cell function [3]. Exposure to intermittent hypoxia (IH), a typ-
ical sign of obstructive sleep apnea, can result in oxidative stress
and subsequent diabetes [4–6]. For instance, pregnant women
with sleep disordered breathing resulting in gestational diabetes
[4,5]. Diabetes is one of the prevalent diseases affected by prenatal
distresses such as hypoxia [5,6]. Such relationships are suggestive
of an association of perinatal exposure to IH and the initiation ofglucose–insulin dysfunction leading to the subsequent develop-
ment of diabetes. However, the identiﬁcation of the mechanism
and factors involved in this process requires an animal model of
perinatal IH induction of diabetic symptoms.
Understanding the diabetogenic mechanism may be a crucial
step to clarify the enigma as to how diabetes mellitus initiates.
Autoimmune reaction has been understood as a pathogenic step
for loosing beta cells in type 1 diabetes. However, there has been
no direct evidence of increased beta cell destruction, decreased
population of beta cells, or accompanied inﬂammation in the early
stage of type 1 diabetes because such defects are noted only after
diabetic symptoms have sufﬁciently advanced. In addition, pres-
ence of pro-inﬂammatory cytokines is often considered as a pre-
ceding indicator for inﬁltration of immune cells in relation to
diabetes [7–9]; yet, there has been no report whether pro-inﬂam-
matory changes such as an increased expression of interleukin-1 or
-6 (IL-1/6) precedes inﬂammation in neonatal stage after short-
term IH challenge. As we focused our research goals strictly on
neonates, we performed in vivo experiments and in vitro analyses
to characterize the IH induced perinatal diabetes in which the
hypoinsulinemia is the result of beta cell dysfunctional under pro-
duction of insulin rather than destruction of beta-cells or increased
insulin resistance.
Fig. 1. Beta cell mass and counts in IH-treated and control animals. In picture (A),
islets are identiﬁed by yellow stain. The difference in beta cell mass was not
statistically signiﬁcant. As shown in (B), the number of beta cells was counted in an
islet demarcated by orange line. The difference in beta cell count was not
statistically signiﬁcant.
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2.1. Preparation of animals
Ten near end-term pregnant Sprague–Dawley rats were main-
tained until parturition. One day after birth, ﬁve dams along with
their respective offspring were randomly selected and designated
the control group. Number of pups per each colony was controlled.
The other ﬁve dams with offspring were designated the experi-
mental group. The two groups included a total of ﬁfty-one male
pups. Female pups were excluded from the study. The animals
were housed in commercially designed chambers with food and
water accessible ad libitum, as previously described [10]. The
experimental animals were maintained at oxygen concentrations
that alternated between room air, 20.8% and 10.3% every 420 s
for 5 h; and the control animals were maintained in room air oxy-
gen concentration for 5 h. Each 5 h preparation was carried out
once per animal. The pups spent approximately 20–30 min every
day with experimenter(s) to minimize stress during the time of
procedures. This study was performed in strict accordance with
the recommendations in the guide for the Care and Use of Labora-
tory Animals of the National Institutes of Health. The experimental
protocol was approved by the Institutional Animal Review Com-
mittee (ARC #2007–008-02) at UCLA and the entire process was
conducted by the highest principles of animal welfare which did
not conﬂict with EU Directive 2010/63/EU.
2.2. Measurements of blood glucose and insulin
After 2 h food deprivation as described by Durham and Truett
[11], the animals were anesthetized with pentobarbital (100 mg/
kg, i.p.), the chest was opened, and at least 1.5 mL of blood was
drawn from the left ventricle of the heart into serum collection
tubes. Separated serum was transferred to 2 mL cryotubes and
immediately frozen at 20 C. Glucose and insulin assays were
out-sourced to the Pathology and Laboratory Medicine Services,
UCLA. Insulin was measured using the MILLPLEX X-Map magnetic
bead-based immunoassay kit by Millipore using Luminex technol-
ogy. Glucose in blood was determined by ACE Glucose reagent
(Alfa Wassermann Diagnostic Technologies, NJ, USA) and the Ve-
tACE Clinical Chemistry System.
2.3. Euthanasia and tissue procurement
Pups were fasted for 2–2.5 h prior to being anesthetized with
pentobarbital (100 mg/kg, i.p.) and perfused with 30 ml of 0.1 M
phosphate-buffered saline. The pancreas was rapidly harvested
from each animal, weighed and divided into two halves; with
one half immediately stored in liquid nitrogen (80 C), and the
other half ﬁxed in cold 10% neutral buffered formalin for parafﬁn
embedding.
2.4. Immunohistochemistry (IHC) for ﬁxed and frozen tissues
Parafﬁn embedded tissues were sectioned at 10 lm thickness
and mounted on slides. The slides with anti-insulin primary anti-
body (guinea pig anti-insulin, Zymed, Invitrogen) at 1:100 dilution
in Tris-buffered saline were used in accordance with manufac-
turer’s guideline. For assessing beta cell mass, the red outline de-
picted the total pancreas area and the yellow areas were
estimated for beta cells (Fig. 1A). Total beta-cell mass was calcu-
lated by multiplying total pancreatic wet weight by the fraction
of the area occupied by insulin-containing cells with respect to
the total area measured by Image-Pro plus 4.1 software (DataCell
Ltd). At least 10 images per rat were scanned.Antibody GAD65 isoform was used to stain with insulin for
identifying insulin-expressing beta cells on frozen sections
(Fig. 1B). Cells were counted manually using the counter tool in
Adobe photoshop. Image J software was used for measuring islet
area and circumference. Digital images of a micrometer with
known measurements were used to set the scale in Image J. Lastly,
H & E staining was performed to examine inﬁltration of inﬂamma-
tory cells and followed by IHC using IL-1b (Rabbit, Santa Cruz, USA)
and IL-6 (Rabbit, Abcam) polyclonal antibodies to assess pro-
inﬂammatory activity in the islets of parafﬁn-embedded pancreata.
All sections were visualized with the diaminobenzidine reaction
and counterstained with hematoxylin. All staining processes were
outsourced.
2.5. Glucose tolerance tests
Glucose tolerance tests (GTT) were performed on a separate day
on control (n = 7) and experimental IH animals (n = 6) without
anesthesia or sedation. The pups were separated from mothers
and deprived of food 2 h prior to the test. Glucose (1.0 g/kg) was
injected i.p. and blood was sampled from the tip of tails at each
time point. A glucometer (Bionime, GM550) and GS550 strips mea-
sured the level of glucose at baseline, 2, 5, 10, 15, 30 and 60 min.
2.6. Islets isolation and ELISA assays for C-peptide
Islet isolation from pancreata harvested from 3 control and 3 IH
treated pups was performed as described by Carter et al. [21].
Immediate after sacriﬁce, cold collagenase solution was injected
into the pancreas through the common bile duct. The removed
pancreas was placed into conical tube for digestion at 37 C for
8 min in collagenase, followed by two-times washing using
Fig. 2. Comparison of serum glucose and insulin levels of IH treated and control
animals. The differences of both blood and insulin are statistically signiﬁcant.
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which dilutes collagenase to slowdown digestive process. Then,
the tissue was ﬁltered through a Netwell Insert 500 lm Polyester
Mesh (Cat# 3480, Corning Inc.). The ﬂow-through was centrifuged
for 2 min at 12,000 rpm and the pellet was re-suspended with
Histopaque 1100 solution (Cat# 10771, 11191, Sigma–Aldrich)
for gradient separation by centrifuging for 20 min at 12,000 rpm.
The supernatant was transferred into a new tube and washed with
G-solution twice. The pellet was resuspended in RPMI 1640 media,
supplemented with 10% FBS and 1% Penicillin–Streptomycin mix-
ture and cultured at 37 C and 5% CO2 incubator for 4 h. After cen-
trifuged for 5 min at 3000 rpm, 20 ll of each supernatant was
taken from control and IH islets in new tubes for C-peptide assay.
Pellets were washed with 1 phosphate-buffered saline. Each pel-
let was incubated with RIPA buffer (Sigma–Aldrich, Inc.) containing
protease inhibitor cocktail (Roche Applied Science) for 15 min on
ice to extract whole cell lysate, and centrifuged at 13,000 rpm for
15 min. 10 lg of cell lysate was used to estimate the amount of
C-peptide produced.
C-peptide were quantiﬁed using an ELISA Kit (Cat# EZRMI-13 K,
EMDMillipore Corporation) in accordance with the manufacturer’s
protocol. Samples were incubated on the monoclonal anti-insulin
coated plate for 2 h, followed by incubation with a horse radish
peroxidase-conjugated anti-insulin antibody. TMB (3,30,5,50-tetra-
methylbenzidine) substrate and the stop solution were added for
the reaction for color changes. Absorbance was measured at
450 nm in a spectrophotometer.
2.7. Statistics
For group comparisons of the insulin and glucose levels, two
tailed t-tests were performed. Beta cell counts were compared
using a non-parametric, Kruskal–Wallis test (SPSS vs. 12.0). Intra-
rater reliability assessment was performed on numbers of beta
cells. Cell counts were performed by the same operator at least
3 weeks apart using the same method. On the results of ELISA,
t-tests were used to assess differences between the groups.3. Results
No visible difference in the activity and behavior were noted be-
tween the control and IH treated pups and mothers. There was no
difference in food and water intake of the control and treated
mothers. Weight was compared between 12 control and 12 IH
treated male pups. No statistical difference was found between
the groups (61.4 ± 5.62 g for control; 62.5 ± 7.19 g for IH treated).
3.1. Blood glucose and insulin measurements in 3 week old rats
The blood glucose level in the IH-treated animals was signiﬁ-
cantly increased by 42% compared to the control animals
(237 ± 20 vs. 167 ± 3 mg/dL; P = 0.003). The level of blood insulin
was decreased by 56% in the IH treated animals compared to the
control animals (807 ± 72 vs. 1839 ± 377 pg/mL, P = 0.023) (Fig. 2).
3.2. Measurements of beta-cell mass and beta-cell counts
Beta cell mass was measured in islet tissues harvested from 5
controls and 5 IH animals (see Fig. 1A). The wet weight of pancreas
in the IH treated and control animals did not differ (328 ± 20 vs.
304 ± 20 mg); and the beta cell mass was unchanged (2.66 ± 0.29
vs. 2.53 ± 0.16 mg). There was no statistical difference in the beta
cell count per unit area of islets for IH treated vs. control animals
(5520 ± 191 and 6157 ± 458), which coincided with the results of
beta cell mass comparisons (Fig. 1B). These collective resultsdemonstrate that the decrease in plasma insulin in the IH treated
pups may not be due to a decrease in the beta cell population.
3.3. Assessing inﬂammation and pro-inﬂammation in the islets
An alternative explanation for the decreased serum insulin level
may be impaired beta cell functions in synthesis or/and secretion
of insulin due to inﬂammation in the islets by IH stress [7,8]. As
shown in Fig. 3A, there is no histological evidence of islet inﬂam-
mation or any other apparent histopathology in either group of
animals. A mild activity of IL-6 in some islets harvested from the
IH treated animals was presented occasionally in contrast to con-
trols (Fig. 3B). Yet, IL-1b activity showed no difference between
the control and IH treated islets. Both IL-1 and -6 are known to
be increased by boosted activity of monocytes which are not
shown anywhere in our samples [12]. Positive control pancreata
obtained from streptozotocin (STZ) injected adult mice donated
other lab show dark stained IL-1b and IL-6 antibody positive beta
cells.
3.4. Assessing function of beta cells
The glucose tolerance tests revealed that the IH treated animals
exhibited blood glucose increased at a faster rate, which peaked at
a signiﬁcantly higher level, and with a more prolonged return to-
ward the initial glucose level (Fig. 4A). These conditions typify an
impaired glucose tolerance response; and thus, the IH treated pups
exhibited abnormal blood glucose regulation.
When ELISA assays were performed to compare functions of
islets obtained from control vs. IH treated animals, the level of
secreted C-peptide (914.46 pM in control vs. 809.41 pM in IH) mea-
sured in media (i.e., which is secreted C-peptide) was signiﬁcantly
different at P = 0.0006, while produced C-peptide protein measured
in cell lysates (312.65 pM/ng in control vs. 313.60 pM/ng in IH)
showed no difference (Fig. 4B).4. Discussion
Type 1 diabetes (T1D) has been characterized as an autoim-
mune form of diabetes, which results in destruction of pancreatic
beta cells; and is often accompanied with inﬂammation of the
Fig. 3. (A) Histological H & E staining of pancreatic tissue obtained from 3 week-old IH-treated and control animals. Neither control nor IH treated animals exhibit any
histological evidence of inﬂammation or other apparent histopathology. The white scale bars in the pictures indicate 50 lm. (B) Immunohistochemistry staining for IL-1b and
IL-6 activities. IH treated pancreas obtained from 3 week old rats exhibit a sign of IL-6 activities in brown color (DAB) that appears milder than the signals in the pancreatic
islets harvested from streptozotocin (STZ) treated mice, positive controls. Control islets show no color changes. Pictures were taken by Aperio ScanScope AT in 20
magniﬁcation. The scale bar indicates 100.3 lm. (For interpretation of color in this Figure, the reader is referred to the web version of this article.)
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sion [13]. In this scenario the destruction of the beta cells is consid-
ered as the cause of the hypoinsulinemia and hyperglycemia. In
our animal model, no evidence exists for involvement of decrease
or destruction of beta cells, nor any histological evidence of inﬂam-
mation in the islets associated with the IH induced T1D. A mild, but
not signiﬁcant, sign of pro-inﬂammatory cytokines was observed
occasionally in islets of IH treated pups, but not yet showed any
potential for full development. Despite the intact anatomy of the
IH treated islets, glucose regulation was apparently impaired;
however, the graphical depiction of glucose tolerance tests shown
in Fig. 4A does not represent a typical shape of either type 1 or 2
diabetes.
The light signals of IL-6 in some IH treated islets alluded above
are unlikely associated with autoimmune-related inﬂammation,
this ﬁnding parallels to the beta cell dysfunction in the absence
of beta cell destruction associated with the development of T1D
observed in monogenic diabetes [14,15]. It brings into question
the validity of a rigid deﬁnition of T1D as resulting from an autoim-
mune condition; particularly in the early initial stage of T1D. Thereare likely numerous etiological conditions and polygenic factors
that can initiate the manifestation of T1D symptoms. It is also
probable that the insulin insufﬁciency and hyperglycemia could
initially arise as an early event; which is then followed by ‘autoim-
mune-like’ inﬂammatory involvement as the condition progresses.
Notably, in the recent excellent review of T1D, Rowe et al. [16] also
challenge the justiﬁcation and rigidity of the autoimmune disease
requirement for T1D. This view has recently received a wider sup-
port in the ﬁeld of autoimmunity [17,18]. A barrier to elucidation
of this issue has been the absence of an ‘appropriate’ animal model
for studying of initiating events in the development of T1D, partic-
ularly in the absence of the inﬂammation in T1D. The animal model
that we describe here may provide these criteria.
Both in vivo and in vitro analyses on our model indicate that the
off-balance in glucose-insulin homeostasis in our IH model appears
not due to anatomical but to functional defects in pancreatic beta
cells after IH stimulation. We measured the level of C-peptide
rather than insulin to assess total proinsulin production. The de-
creased C-peptide secretion from the islets harvested from IH trea-
ted animals indicates a decrease of the total insulin secretion in
Fig. 4. Glucose tolerance tests (GTT) and secretion of C-peptide. (A) GTT results show a signiﬁcant difference at 10 and 15 min points. At 30 min point, the glucose level
returns to the baseline in control pups. (B) C-peptide concentrations measured from each medium signiﬁcantly differed between control and IH treated groups, whereas the
measurements obtained from cell lysates remain the same.
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sates suggests no change in proinsulin production in the islets after
IH treatment. Therefore, we could assume some impairment in
cleaving or releasing process of insulin along the manufacturing
system after IH challenge [19]. We also can conclude that this dys-
function is not likely associated with type 2 diabetes which is often
characterized by hyperproinsulinemia [20]. Plausible underlying
reasons could be damaged endoplasmic reticulum (ER) by reactive
oxygen species (ROS) since depleting ER calcium due to stress leads
to protein misfolding [21] or an elevated mitochondrial ROS which
down regulates the conversion of proinsulin to insulin [22]. How-
ever, again, we did not observe any evidence of C-peptide increase
which approximates proinsulin accumulation in beta cells in our
short term study.
Animal studies reported on metabolic effects of spontaneous
neonatal IH exposure are rare [23]. A recent study by McPherson
et al. [24] showed that postnatal maternal separation may be a sig-
niﬁcant additive causal factor in developing metabolic syndrome in
later age. Our animal protocol which successfully minimized po-
tential stress in pups by accompanying their mothers throughout
the experiment and acclimatizing them by spending 20–30 min
with an experimenter daily for 3 weeks; thus, we were able to rule
out, or at least minimize, any potential inﬂuence of stress from
parental separation on glucose and insulin levels. We report this
based on preliminary observations; therefore, we do not know
whether the current form of diabetic onset belongs to T1D, T2D
or double diabetes which is an emerging question of the ﬁeld
[25] or simply, a clinical expression of temporary mismatch be-
tween beta cell function and beta cell mass [26]. We do not know
whether this dysfunction in glucose homeostasis would progress
as the pups age because the dysfunction could be due to a remnant‘‘toxicity’’ from IH stimulation. As discussed by many others [27],
assuming diabetes onset based on beta cell mass is an ongoing con-
troversial topic. In this report, we have described an animal model
for the study of the implications of IH in the early development of
diabetes. The model permits the identiﬁcation of hypoinsulinemia
and accompanying hyperglycemia in the absence of autoimmune-
like inﬂammatory conditions that accompany the later progression
of diabetes. We recognize that additional studies on the underlying
mechanism including genetic tests are necessary to establish fur-
ther the characteristics of this model.
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